Indaptus Therapeutics, Inc.
INDP · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $6,054 | $144,078 | $220,608 |
| - Cash | $5,826 | $6,158 | $3,891 | $5,787 |
| + Debt | $0 | $34 | $60 | $84 |
| Enterprise Value | – | -$69 | $140,246 | $214,905 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$2,975 | -$5,229 | -$4,573 | -$4,131 |
| % Margin | – | – | – | – |
| Net Income | -$2,975 | -$5,229 | -$4,532 | -$4,131 |
| % Margin | – | – | – | – |
| EPS Diluted | -2.98 | -9.1 | -0.48 | -0.38 |
| % Growth | 67.3% | -1,795.8% | -26.3% | – |
| Operating Cash Flow | -$3,055 | -$4,018 | -$5,047 | -$3,396 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$3,055 | -$4,018 | -$5,047 | -$3,396 |